Wegovy vs. Contrave
Wegovy and Contrave both target chronic weight management, but their mechanisms and results differ. Wegovy, a GLP-1 receptor agonist, slows gastric emptying and reduces appetite, resulting in an average weight loss of 15% of one's bodyweight. Contrave combines naltrexone and bupropion to affect appetite and reward pathways, achieving less pronounced weight loss. Neither drug has notable off-label uses. Both share nausea as a common side effect, but Contrave may also cause insomnia and mood changes due to its neurological components. Wegovy’s monthly cost ($1,375) is significantly higher than Contrave’s $300. Neither faces current shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Bupropion enhances dopamine and norepinephrine activity, reducing appetite and cravings; Naltrexone modulates the brain’s reward system, reducing cravings and emotional eating behaviors by blocking opioid receptors.
Common Side Effects
Nausea, constipation, headache, dizziness, dry mouth, and insomnia.
Serious Potential Side Effects
Increased blood pressure, seizures (rare), suicidal thoughts, and liver damage.